Michael J. Wise

Michael J. Wise's interest in IP law was piqued in high school after he read an article about the technologies that would replace audio and video tapes -- CDs and DVDs -- and the patenting of these new mediums.

"But I was more interested in biology than electronics. So, at that time I was keenly interested in the emerging area of biotechnology," he said. "For example, I can still recall where I was when I learned that Genentech went public. At the time I was living in Portland, Maine and I decided to move to California to become a biotech patent lawyer which was my dream job."

He took the patent bar in his first year of practice and started working at Lyon & Lyon, a patent boutique, in 1990.

Since then, he has joined Perkins Coie LLP and now leads more than a dozen patent lawyers focused on implementing a comprehensive and coordinated patent litigation, IPR strategy and prosecution for cutting edge technology. His clients over the past 25 years have ranged from large academic and research institutions such as California's City of Hope to Fortune 100 companies.

Recently, Wise and his team are representing Take2 Technologies and the Chinese University of Hong Kong against PacBio for infringement of the University's patent. Take2 Technologies Limited and the Chinese University of Hong Kong v. Pacific Bioscience of California, Inc., 22-cv-1595 (D. Del., filed Dec. 14, 2022).

The matter was related to the determination of base modifications of nucleic acids.

"We filed the case in Delaware and PacBio successfully moved to transfer the case to California," Wise said. "In California, we successfully moved to disqualify the PacBio legal department from the case and defeated PacBio's motion to dismiss."

Wise is also lead counsel on behalf of Amgen, who is accused of biopharmaceutical company Lindis of infringing three patents related to using glucocorticoids with certain types of biologic therapeutics. The case is scheduled for trial in 2024. GMBH v. Amgen Inc., 1:22-cv-00035 (D. Del., filed Jan. 10, 2022).